Share Name Share Symbol Market Type Share ISIN Share Description
Ultrasis LSE:ULT London Ordinary Share GB0001494979 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.095 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 1.83 -1.44 -0.08 2
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.095 GBX

Ultrasis (ULT) Latest News

Real-Time news about Ultrasis (London Stock Exchange): 0 recent articles
More Ultrasis News
Ultrasis Investors    Ultrasis Takeover Rumours

Ultrasis (ULT) Discussions and Chat

Ultrasis Forums and Chat

Date Time Title Posts
18/6/202119:23Ultrasis/Screenetics/u2 Interactive Health Care.13,227
20/1/202011:47Ultrasis - Interactive Healthcare35,336
20/1/202010:58Ultrasis/Screenetics/u2 Interactive Health Care.1,131
19/1/202011:54Where is Ultrasis Heading?2,740
18/1/202021:48Pab, the enemy within64

Add a New Thread

Ultrasis (ULT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Ultrasis trades in real-time

Ultrasis (ULT) Top Chat Posts

woollworth: Morning humph 46p is an indicator, I still see a strong resemblance with our other stock, only difference is the share price being much higher, opti have the equivalent investor group ie - elrampo, same RNS wording! Lot of RNS wording very similar written by those with vested interest being paid in full regardless and at investors expense, jury still out on this, if the RNS is accurate the price will creep up, if there's a flaw we're in for more pain, major investors will be advised if the RNS is worth further investment to make profit, few have seen profit over the past two years...manc will not understand this post, too scared of negative comment. Jury out...
woollworth: man one day you will learn, I used to post like you, if you get wiped out your opinion will change, where is this fund at 9%, where is proof it can perform during the rest of 21, what are the risks, tie in term. You need to learn, nothing I say will effect the sp, there is something wrong with this company, hence the falling shareprice, only winners are the bod who get paid regardless, same old stockmarket problem, especially in the aim.Gaim. If it mattered what is said, lse is full of rampers, this should send share price north, but no. From your attitude I assume you bought low, unfortunately some like myself didn't, when I bought rampers were ramping the pants off it, I fell for it now paying the price, lock in for months. This is not the time to praise SOH, he's unaffected by share price drop and never will be. My posts will always be negative until the company prove their worth, new staff is not the way forwards, nor nasdaq listing because of cost.
manc10: wokeworth stop getting emotional with 1p drops you must have everything you own in opti a stock you chose to invest in yourself if the share price was 122 again would you still be crying answer no my advice is put your money in a fund and take 9% a year
woollworth: humph like I said its reacting like ult at higher price, never made sense either. Price same as early days, 18 months waiting but a gradual decline, problem is they have all those extra wages to pay, holiday pay, pension contributions, expenses, cars, extra office staff to cope with more peeps on the books, draining income at high rate. AIM is badly manipulated throughout, got sell on profit or remain locked in till dooms day :) SBTX holders made a killing at our expense, eventually newbies will end the same as us, those buying at today price. 2022 it could look better but my guess promise of profit will not happen, due to new staff wages added to existing, gravy train stock, we continue to pay the price with our losses.
woollworth: elrampo again, nothing changes humph, those type of figures mean nothing as proven over the past 12 months, why would a firm boasting profit at the same time employ numerous staff, this will stop profit, wait for their excuses. We received numerous posts saying similar on the ult thread, remember ult RNS multi million public sector contract, followed by bust. People that put those figures together are financially involved, ie its coming from the bod on full pay regardless of our loss, at their gain, they need to ramp up investors so they can continue their cash cow, don't trust humph, same as the governbent, do not trust 75% of their BS....
humphries1: Hi wooly yep share price of SBTX takes the biscuit with no revs yet and OPTI have, even the value of SBTX should make a diff to OPTIs share price it don't make sense, maybe share holders of SBTX could be valuing in the new drug trial, perhaps when results of trial are out the share price will do an OPTI and drop big time
woollworth: humph unsure where opti is going, something is wrong when looking at skin share price Sure they are staff heavy eating away income, my guess without a miracle a cash call is later 21, use opti as a cash cow, same as ult, creating numerous businesses around ult brand. Think about those new staff and advisors eating away income!
humphries1: D read this and you will see why i wont buy into any other share. this is the bit that gets my juices flowing 9. SweetBiotix (R): There has been good progress of the Company's manufacturing partner who are in the process of manufacturing an initial run of two metric tonnes of SweetBiotix(R). This will be the first industrial scale manufacture of SweetBiotix(R) products. The manufacturing scale up of SweetBiotix(R) is being paralleled by the release of a number of independent peer reviewed publications demonstrating prebiotic activity and superior taste profile and open innovation application development with global partners. 17 March 2021 Opti B i otix Health plc ( "Opti Bi o t ix" or the "Company") Commercial strategy update OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, provides an update on the progress of its commercial strategy. The strategy is designed to build brand presence and early sales of OptiBiotix's first generation functional ingredients LP(LDL) (R), SlimBiome(R), and WellBiome(R) and establish a global network of partners. This provides the base of a sustainable business with the probiotic and functional fibre divisions achieving profitability in 2020. Now this has been achieved, the next phase of the strategy is to scale the commercially established first generation product sales by extending product lines and territories with existing partners, and grow profitability by moving up the value chain to sell more product than ingredients. This increases revenues and margin and has a compounding revenue effect in pulling through ingredients sales. This will be accompanied by a focus on commercialising next generation products including the microbiome modulators, LP(LDL) (R) as a drug biotherapeutic, and the growing suite of SweetBiotix(R) products. This Company update is intended to report progress against that strategy: 1. Extension of product range with Holland and Barrett ("H&B") : H&B have launched an extended range of products under their own in-house SlimExpert brand in addition to SlimBiome(R) shots. This extends the number of products containing SlimBiome(R) from three to eight, more than doubling H&B's product offering. The new product range comprises three flavours of meal replacements and two porridge flavours and are a direct result of H&B tasting and testing OptiBiotix's finished product applications available from its online store. The doubling of a product offering and creation of H&B's new own brand range is a big commitment to SlimBiome(R) by a major retailer. 2. Launch of SlimBiome and OptiBiome products in Asia: Primo trading have launched a range of products called Prym Fiber through Amata Life Plus in Thailand. This follows on from the launch of a slimming green tea (OB-EX) containing SlimBiome through the same partner. In addition, Maxcare Inc, have launched a mixed berry flavour SlimBiome jelly stick in Taiwan through a major online TV shopping channel. The launch of products in the region is intended to increase market awareness of the Company's functional ingredient brands in Asia as a forerunner to launching finished products in the larger Asian markets like Singapore and China. OptiBiotix has a distribution agreement with United Italian Trading Corporation (Pte) Ltd for CholBiome(R)(X3) and SlimBiome(R) Medical and anticipates launches of these products in Singapore in early Q2 2021 and China contributing revenues this fiscal year. 3. Agreements to distribute final products in Africa: OptiBiotix has signed agreements with Dipromed, a distributor of food supplements and medical devices, for the sale of SlimBiome(R) Medical and CholBiome(R) products in Morocco and Algeria. Revenue generation is anticipated in 2021 dependent on registration of the products in the territories. 4. Extension of SlimBiome in India: Anthem Biosciences have extended their existing product range of Metalite pro in India and Zeon Lifesciences have launched the ZeoSlim range of meal replacements in India. Dr Taru joins the team on 17 March to build on these early successes and grow sales in the strategically important Indian and Asian markets. Given the size of this market and the scale of the partners the Company are in discussions with, the team anticipate India making a substantial contribution to sales growth in the future. 5. USA product launch: The Company has launched the Dietworks Appetite control gummies in the USA. Dietworks is a specialised US weight management company which sells products through online and retail channel across the USA. This is another point of access to the large US market. 6. Actial Farmaceutica Srl: Due to a high level of customer interest, Actial Farmaceutica Srl ("Actial"), owner of one of the world's best known probiotic brand called VSL(#) 3(R), have requested and been granted an extension to distribute CholBiome(R) and CholBiome(R)(X3) under the VSL#Cardio(R) range to two new territories (France and Malaysia) in addition to the existing territories (Australia, New Zealand, Indonesia and Thailand). Actial sell clinically proven products into the high value pharma, GP, and hospital networks. It is anticipated that an ongoing roll out of products with Actial in an increasing number of territories will continue throughout this financial year. 7. Stability studies: a. SlimBiome(R) Medical has received regulatory approval for 36 months shelf life b. CholBiome and CholBiome(X3) have achieved 24 month stability c. CholBiome(X3) has achieved stability in zone 4b (temp 30C 75% relative humidity). This includes countries such as India, Southern Asia, Africa, and parts of the Middle east and South America. Long term stability studies are important as they are a prerequisite for regulatory approval in many countries, large corporate partners, and international retailers. OptiBiotix has at least 24 months stability for its SlimBiome(R) and LP(LDL) (R) products. This allows OptiBiotix and its partners to place larger orders reducing the cost of goods and increasing margins. The lower cost of goods and zone 4b stability studies are important for product launches in India, Southern Asia, and many middle Eastern and South American markets and is a precursor for orders with our existing partners in these regions. 8. Turnkey solutions: As OptiBiotix focuses on selling more product than ingredients it has developed an extensive range of marketing flyers, scientific publications, videos, graphic, case studies and a science data package to support its partners. It also provides turnkey websites which link directly to payment solutions in multiple languages. These include: hxxps://; hxxps:// ; hxxps://; hxxp://; hxxps://; hxxps:// The overall aim is to make it as easy as possible for partners to market and sell OptiBiotix's final products in different territories around the world. 9. SweetBiotix (R): There has been good progress of the Company's manufacturing partner who are in the process of manufacturing an initial run of two metric tonnes of SweetBiotix(R). This will be the first industrial scale manufacture of SweetBiotix(R) products. The manufacturing scale up of SweetBiotix(R) is being paralleled by the release of a number of independent peer reviewed publications demonstrating prebiotic activity and superior taste profile and open innovation application development with global partners. 10. LP(LDL) (R) drug biotherapeutic : The Company has employed Christopher Nother on a part time consultancy basis to explore the use of LP(LDL) (R) in pharma, either as an 'over the counter' (OTC) product, or a drug biotherapeutic in markets outside the USA. LP(LDL) (R) has already received an investigational New Drug Approval with Seed Health for a Phase II pharma clinical study. The Company will shortly be publishing placebo controlled human studies which show LP(LDL) (R) can achieve similar reductions in total cholesterol and LDL (bad cholesterol) to statins, without any side effects. Early discussions suggest that ProBiotix's existing humans studies provide safety, tolerance, and efficacy comparable to that typically seen in a Phase II pharma study. If this is confirmed the risk, timeline, and costs to develop LP(LDL) (R) as a drug biotherapeutic is substantially reduced. Chris is currently assessing the costs and timelines to develop LP(LDL) (R) as a drug biotherapeutic and the potential to create a biotherapeutic drug division or separate Limited company to fully exploit the opportunity and potential for significant upside. Stephen O'Hara, CEO of OptiBiotix Health plc c o m mented: " The Company is in a pivotal position in reporting profitability within its divisions from early sales of our first generation products whilst building the scientific and clinical evidence base to de-risk our highly innovative second generation products. These offer the potential to open significantly larger market opportunities whilst having a low overhead sustainable business model from which to rapidly scale. Strong progress in Q1 2021 with manufacturing scale up of SweetBiotix, development of LP(LDL) (R) as a drug biotherapeutic, product line and territory extensions of existing products with corporate and retail partners, coupled with progress in the Indian and Asian markets, puts the Company in a strong position for future growth in this exciting area of healthcare."
woollworth: I stick like humph d4 and paying the price, my money should have gone into sweet, totally outperforming its main company opti, share price price well below 2016 and no sign of recovery. Nasdaq listing will cost money they don't have, add on new staff an advisors, can see where this is going, possible they will need money because of hefty staffing cash burn imo. Unless sweet bails their gravy train out.
woollworth: humph a 22k buy this morning, if they decided to sell a couple of hours later, 2p loss per share, the share price will never rise while investors are seeing that happen to their hard earned.
Ultrasis share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210621 05:14:41